The chimeric antigen receptor T (CAR-T) cells play an antileukemia role, and can be used to treat or prevent relapse by targeting minimal residual disease for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the infusion of allogeneic CAR-T cells may also cause graft-versus-host disease, which limited their applications during and after allo-HSCT. In this review, we discuss the clinical trials that applying CAR-T cells before allo-HSCT and the use of donor-derived CAR-T cells as conditioning regimen during allo-HSCT. At last, we analyzed the effect of donor-derived CAR-T cells on preventive infusion after allo-HSCT.
CITATION STYLE
Liu, J., Zhang, X., Zhong, J. F., & Zhang, C. (2019). Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation. Immunotherapy, 11(1), 37–44. https://doi.org/10.2217/imt-2018-0089
Mendeley helps you to discover research relevant for your work.